ACP
Acuta Capital Partners Portfolio holdings
AUM
$71.6M
This Quarter Return
+46.68%
1 Year Return
+169.78%
3 Year Return
+1,553.75%
5 Year Return
+4,509.01%
10 Year Return
+155,159.98%
AUM
$363M
AUM Growth
+$363M
(+6.7%)
Cap. Flow
-$33.2M
Cap. Flow
% of AUM
-9.14%
Top 10 Holdings %
Top 10 Hldgs %
48.6%
Holding
60
New
16
Increased
14
Reduced
15
Closed
8
Top Buys
| 1 |
VistaGen Therapeutics
VTGN
|
$14.6M |
| 2 |
BLSA
BCLS Acquisition Corp. Class A Ordinary Shares
BLSA
|
$9.39M |
| 3 |
Replimune Group
REPL
|
$7.92M |
| 4 |
JYAC
Jiya Acquisition Corp. Class A Common Stock
JYAC
|
$5.79M |
| 5 |
Stoke Therapeutics
STOK
|
$5.73M |
Top Sells
| 1 |
IMMU
Immunomedics Inc
IMMU
|
$43.5M |
| 2 |
Kura Oncology
KURA
|
$11M |
| 3 |
Aldeyra Therapeutics
ALDX
|
$9.98M |
| 4 |
Cytokinetics
CYTK
|
$7.74M |
| 5 |
LSACU
LifeSci Acquisition Corp. Unit 1 COM & 1 WT
LSACU
|
$7.62M |
Sector Composition
| 1 | Healthcare | 90.62% |
| 2 | Financials | 4.18% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Celldex Therapeutics
CLDX
$1.47B
| $28.5M | 7.76% | 1,627,500 +82,500 | +5% | +$1.45M |
|
|
SAGE
2
DELISTED
Sage Therapeutics
SAGE
| $22.1M | 6.02% | 255,800 +30,800 | +14% | +$2.66M |
|
|
3
Kura Oncology
KURA
$686M
| $20.8M | 5.67% | 637,500 -335,500 | -34% | -$11M |
|
4
Larimar Therapeutics
LRMR
$310M
| $18.5M | 5.03% | 863,100 +33,100 | +4% | +$709K |
|
5
Mersana Therapeutics
MRSN
$36.5M
| $18.5M | 5.03% | 694,000 +26,500 | +4% | +$705K |
|
|
CMPS
6
Compass Pathways
CMPS
$424M
| $15.2M | 4.14% | 319,000 -71,000 | -18% | -$3.38M |
|
|
7
VistaGen Therapeutics
VTGN
$102M
| $14.6M | 3.96% | +7,500,000 | New | +$14.6M |
|
8
Athira Pharma
ATHA
$15.3M
| $13.5M | 3.66% | 393,000 +30,500 | +8% | +$1.04M |
|
9
Immunovant
IMVT
$2.56B
| $13.1M | 3.56% | 283,500 +33,500 | +13% | +$1.55M |
|
|
TRIL
10
DELISTED
Trillium Therapeutics Inc.
TRIL
| $11.8M | 3.21% | 803,000 -50,000 | -6% | -$735K |
|
11
Arrowhead Research
ARWR
$3.05B
| $10.7M | 2.9% | 139,000 +37,500 | +37% | +$2.88M |
|
12
89bio
ETNB
$1.34B
| $10.6M | 2.88% | 434,400 +16,900 | +4% | +$412K |
|
13
Syndax Pharmaceuticals
SNDX
$1.41B
| $10.4M | 2.82% | 465,500 +224,756 | +93% | +$5M |
|
14
Apellis Pharmaceuticals
APLS
$3.48B
| $9.56M | 2.6% | 167,054 | – | – |
|
|
BLSA
15
DELISTED
BCLS Acquisition Corp. Class A Ordinary Shares
BLSA
| $9.39M | 2.55% | +842,500 | New | +$9.39M |
|
|
SURF
16
DELISTED
Surface Oncology, Inc. Common Stock
SURF
| $9.24M | 2.51% | 999,500 -88,500 | -8% | -$818K |
|
17
Gyre Therapeutics
GYRE
$703M
| $8.57M | 2.33% | 1,357,500 -140,400 | -9% | -$886K |
|
|
ISEE
18
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
| $8.38M | 2.28% | 1,212,500 +410,000 | +51% | +$2.83M |
|
19
Fulcrum Therapeutics
FULC
$351M
| $7.99M | 2.17% | 682,500 +301,000 | +79% | +$3.52M |
|
|
20
Replimune Group
REPL
$422M
| $7.92M | 2.15% | +207,500 | New | +$7.92M |
|
21
Iovance Biotherapeutics
IOVA
$807M
| $7.65M | 2.08% | 164,800 -150,200 | -48% | -$6.97M |
|
|
CNCE
22
DELISTED
Concert Pharmaceuticals, Inc.
CNCE
| $6.79M | 1.85% | 537,500 +237,500 | +79% | +$3M |
|
23
Altimmune
ALT
$338M
| $6.53M | 1.78% | 578,500 -109,500 | -16% | -$1.24M |
|
24
Avidity Biosciences
RNA
$5.99B
| $6.28M | 1.71% | 246,200 +11,200 | +5% | +$286K |
|
|
JYAC
25
DELISTED
Jiya Acquisition Corp. Class A Common Stock
JYAC
| $5.79M | 1.58% | +562,500 | New | +$5.79M |
|